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ABSTRACT
Pancreatic cancer is one of the most aggressive and lethal types of cancer, and 
more effective therapeutic agents are urgently needed. Overexpressed cell surface 
antigens are ideal targets for therapy with monoclonal antibody (mAb)-based drugs, 
but none have been approved for the treatment of pancreatic cancer. Here, we 
report development of two novel mouse mAbs, KU42.33C and KU43.13A, against the 
human pancreatic cancer cell line BxPC-3. Using ELISA, flow cytometry, competitive 
assay and immunoprecipitation followed by mass spectrometry, we discovered 
that these two mAbs target two distinct epitopes on the external domain of CD109 
that are overexpressed by varying amounts in human pancreatic cancer cell lines. 
Treatment with these two naked antibodies alone did not affect tumour cell growth 
or migration in vitro. Of the two mAbs, only KU42.33C was useful in determining the 
expression of CD109 in tumour cells by Western blot and immunohistochemistry. 
Interestingly, immunohistochemistry of human pancreatic carcinoma tissue arrays 
with mAb KU42.33C showed that 94% of the 65 human pancreatic adenocarcinoma 
cases were CD109 positive, with no expression in normal pancreatic tissues. Our 
results suggest that these two novel mAbs are excellent tools for determining the 
expression level of CD109 in the tumour specimens and sera of patients with a wide 
range of cancers, in particular pancreatic cancer, and for investigating its diagnostic, 
prognostic and predictive value. Further research is warranted and should aim to 
unravel the therapeutic potential of the humanised forms or conjugated versions of 
such antibodies in patients whose tumours overexpress CD109 antigen.
INTRODUCTION
Pancreatic cancer is one of the most aggressive 
and lethal types of cancer with a five-year survival rate 
of ~5% which has barely improved in the past four 
decades [1]. In 2012, there were an estimated 337,872 
new cases and 330,391 deaths as a result of pancreatic 
cancer worldwide [1]. Treatment of pancreatic cancer 
requires a multidisciplinary approach that includes 
surgery, chemotherapy, radiotherapy and palliative care. 
Surgery is indicated in patients with localised disease, 
accounting only for 10-20% of cases, and is followed 
by adjuvant chemotherapy [2]. Treatment of metastatic 
disease is based on gemcitabine-containing regimens, 
sometimes in combination with erlotinib or more 
recently with nab-paclitaxel although such combinations 
only offer modest survival benefit in some patients in 
comparison with gemcitabine alone [3–5]. Treatment with 
gemcitabine-free FOLFIRINOX (leucovorin, fluorouracil, 
irinotecan, oxaliplatin) has improved the median overall 
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survival compared with gemcitabine alone (11.1 vs 6.8 
months), but this combinational therapy is accompanied 
by increased side effects and thus is often an option for 
younger patients with good performance status [6]. There 
is currently no reliable biomarker or screening method 
for the early detection of pancreatic cancer and novel and 
more effective therapeutics are urgently needed. Moreover, 
without further advances in these fronts, pancreatic cancer 
is projected to bypass breast, prostate and colorectal 
cancers, and become the second leading cause of cancer 
deaths after lung cancer in the USA by 2030, and the third 
leading cause of cancer death in European Union after 
lung and colorectal cancer by 2025 [7, 8].
Monoclonal antibody (mAb) technology is 
an excellent tool for the identification of novel and 
overexpressed cell surface antigens in human malignancies 
and mAb-based products have untapped therapeutic 
and diagnostic potential in cancer. Indeed, the exquisite 
specificity of mAbs for their target antigens makes them 
an attractive approach for targeted cancer therapy [9–14]. 
To date, 32 mAbs have been approved for cancer treatment 
in the U.S. and/or European Union. However, none have 
yet been approved for pancreatic cancer [15–18]. Our aim 
was to develop novel mAbs of diagnostic and therapeutic 
potential against overexpressed cell surface antigens 
on human pancreatic cancer cells. Here, we report the 
development of two novel mouse mAbs against distinct 
epitopes on the extracellular domain of CD109, using the 
human pancreatic cancer cell line BxPC-3 as the source of 
tumour immunogen. We showed that the CD109 antigen 
is overexpressed in several human pancreatic cancer cell 
lines and pancreatic cancer tissue array, with no expression 
in normal pancreatic tissues. The characterisation of these 
antibodies and their potential for use as diagnostic and 
therapeutic agents are discussed.
RESULTS
Development of two novel mouse mAbs 
KU42.33C and KU43.13A
Several hybridoma were generated by the fusion of 
lymphocytes, isolated from the spleens of mice immunised 
with BxPC-3 cells, and the myeloma cell line SP2. The 
hybridomas’ supernatants were screened against a panel 
of human pancreatic cancer cell lines established from 
patients at different stages of their disease including 
primary tumours (BxPC-3, Capan-2, MIA PaCa-2, PANC-
1), liver metastatic tumours (CFPAC-1, Capan-1), ascites 
(HPAF-II, AsPC-1) and lymph node metastasis (Hs 766T). 
The results of ELISA screening showed that the antibodies 
secreted by two hybridomas, KU42.33C and KU43.13A, 
were against an antigen with high level of expression in 
some of the human pancreatic cell lines (e.g. BxPC-3, 
PANC-1, FA-6 and MIA PaCa-2, Supplementary Figure 
1). However, the target antigen recognised by mAbs 
KU42.33C and KU43.13A was found to be trypsin-
sensitive and there was no binding when screened by 
flow cytometry (data not shown). Therefore, an enzyme-
free cell dissociation buffer was used for cell detachment 
prior to flow cytometry analysis. Following optimisation, 
high level of expression of the target antigen was found 
with both mAbs KU42.33C and KU43.13A in some of 
the human pancreatic cancer cell lines including BxPC-
3 (MFI=86 and 90), Capan-2 (MFI=19 and 16), MIA 
PaCa-2 (MFI=56 and 57), PANC-1 (MFI=45 and 56), 
CFPAC-1 (MFI=21 and 19) and FA-6 (MFI=39 and 36, 
respectively), compared to negative control (Figure 1, 
Supplementary Figure 2). In contrast, the expression of 
the target antigen in other human pancreatic cancer cell 
lines namely Capan-1, AsPC-1, HPAF-II and Hs766T was 
found to be negative or lower with MFI values ranging 
from 2-12 (Figure 1, Supplementary Figure 2). We also 
examined the level of expression of the target antigen in 
other cancer cell lines including human head and neck 
squamous carcinoma HN5 and breast cancer cell lines 
MDA-MB-468 and SKBR-3. High level of the target 
antigen was present in both HN5 and the triple negative 
breast cancer cell line MDA-MB-468, but not in the HER-
2 overexpressing breast cancer cell line SKBR-3 (Figure 
1, Supplementary Figure 2).
Both novel mAbs were purified by affinity 
chromatography and were found to be of IgG1κ isotype 
(Supplementary Figure 3). To determine whether the two 
antibodies were directed against the same, overlapping or 
distinct epitopes on the target antigen, competitive ELISA 
was performed. For this, saturation of the antigen binding 
site was initially performed with one the mAbs prior to 
addition of the second antibody to explore if absorbance 
value increased further. The absorbance curve for mAb 
KU42.33C plateaued at concentrations higher than 50 μg/
ml. Thereafter, only additional doses of mAb KU43.13A 
increased the absorbance (Figure 2). These results support 
that mAbs KU42.33C and KU43.13A recognise non-
overlapping epitopes on the extracellular domain on the 
target antigen.
The two novel mAbs KU42.33C and KU43.13A 
are against CD109 on human pancreatic cancer 
cells
Both mAbs, KU42.33C and KU43.13A, 
immunoprecipitated a ~170 KDa protein identified as 
CD109 by mass spectrometry (Figure 3A and Table 
1). In addition, mAb KU42.33C immunoprecipitated 
faint bands of ~150 KDa and ~80 KDa (Figure 3A). 
However, in Western blot, only KU42.33C detected the 
CD109 bands of 170 KDa and 150 KDa, suggesting that 
KU43.13A is directed against a conformational epitope 
on CD109 antigen (Figures 3B). Furthermore, to confirm 
that these two antibodies were directed against CD109, 
BxPC-3 tumour lysates were immunoprecipitated with 
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the two novel antibodies, transferred by Western blot and 
then probed with a commercial anti-CD109 antibody. As 
shown in Figure 3C, the commercial antibody detected 
the CD109 antigen immunoprecipitated by both of the 
novel mAbs. These results suggest that mAbs KU42.33C 
and KU43.13A are directed towards a sequential and a 
conformational epitope on CD109 antigen, respectively.
Effect of novel mAbs KU42.33C and KU43.13A 
on tumour growth and migration and cellular 
location of CD109
Next, we examined the effect of treatment with the 
two novel antibodies on growth and migration, in vitro, of 
a panel of human pancreatic cancer cell lines. At maximum 
concentration of 300 nM, mAbs KU42.33C and KU43.13A 
did not affect the growth of the human pancreatic cancer 
cell lines nor inhibited the migration of BxPC-3, AsPC-1 
and CFPAC-1 cells (data not shown). We also examined 
the cellular location of the target antigens recognised by 
the mAbs. As shown in Figure 4A, the CD109 antigen 
recognised by these novel mAbs is located on the surface 
of human pancreatic cancer cells. In addition, there was 
no evidence of CD109 downregulation and internalisation 
following antibody treatment for 30 min at 37ºC (Figures 
4A & 4B). The anti-EGFR mAb HM43.16B was used as 
a control and treatment with this antibody resulted in the 
EGFR downregulation and internalisation (Figure 4A).
The application of mAb KU42.33C in 
immunohistochemical detection of CD109 in 
pancreatic cancer
To explore the diagnostic potential of the novel 
mAbs, immunohistochemical staining of CD109 positive 
BxPC-3 tumour cell pellets was investigated. Our results 
showed that only mAb KU42.33C, which was found to be 
against a sequential epitope by Western blot analysis as 
described above, detected the antigen in formalin-fixed, 
paraffin-embedded tissue sections (Figure 5A and 5B). 
Further optimisation, including antigen retrieval with Tris-
EDTA pH 9.0 buffer and signal amplification, resulted in 
stronger immunostaining of CD109 (data not shown). 
Next, we examined the relative expression of CD109 
antigen by mAb KU42.33C in human pancreatic cancer 
tissue arrays containing 70 specimens from patients with 
pancreatic adenocarcinoma. Of these, five samples were 
either necrotic or contained no tumour and therefore were 
excluded from the study. Of 65 cases, 94% were CD109 
positive, with intensity ranging from 1+ (n=55, 85%) to 2+ 
Figure 1: Expression level of the antigens recognised by novel mAbs KU42. 33C and KU43.13A on human pancreatic 
cancer and other cancer cell lines, determined by flow cytometry. Data is presented as Mean Fluorescence Intensity (MFI) ± SD.
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(n=6, 9%). Staining predominated in the membrane and 
the cytoplasm of cancer cells and did not correlate with 
the disease grade (Figure 5C-5G; Supplementary Table 
1). In contrast, normal pancreatic tissue was negative 
or showed weak diffuse staining possibly attributable to 
technical artefact (Figure 5H). There was no staining in 
the absence of primary antibody-control (data not shown). 
Interestingly, with the exceptions of weak staining (1+ 
intensity) of normal tissues from ovary and small intestine, 
all the remaining 31 normal tissues from the following 
organs were CD109 negative: cerebellum, cerebral cortex, 
pituitary gland, spinal cord, eye, adrenal gland, thyroid, 
parathyroid adenoma, thymus, tonsil, bone marrow, kidney, 
bladder, prostate, testis, uterine cervix, endometrium, 
fallopian tube, oesophagus, stomach, colon, rectum, liver, 
pancreas, spleen, lung, heart, breast, placenta, striated 
muscle and skin (Supplementary Table 2).
DISCUSSION
Pancreatic cancer is projected to become the 
second leading cause of cancer deaths in the USA by 
2030 [7]. There is an urgent need to discover novel 
biomarkers of diagnostic, prognostic and predictive 
values and therapeutic targets in patients with pancreatic 
cancer. As mAb-based products are highly specific for 
their target antigens, they have been routinely used as 
diagnostic and therapeutic agents in many pathological 
conditions including cancer [9–12, 17–18]. Moreover, 
mAb technology is an excellent tool for the discovery of 
novel overexpressed cell surface tumour antigens and the 
study of their functions. Here, we report the generation 
of two mAbs, KU42.33C and KU43.13A, against two 
distinct epitopes on the external domain of CD109, using 
the human pancreatic cancer cell line BxPC-3 as the 
source of tumour immunogen. We have shown that the 
antigen recognised by these antibodies is overexpressed 
on the cell surface of BxPC-3 and other human pancreatic 
cancer cell lines by varying amounts (Figures 1 and 4A). 
However, treatment with these two antibodies did not 
affect the proliferation or migration in vitro of CD109 
overexpressing cancer cell lines (data not shown), 
nor resulted in the down-regulation of CD109 antigen 
(Figure 4). Interestingly, of the two antibodies, only mAb 
KU42.33C recognised the CD109 antigen by Western blot 
(Figure 3B), which suggests that both mAbs are directed 
against different epitopes of the same antigen (Figure 2).
Originally identified by mAbs raised against the 
primitive CD34+ acute myeloid leukaemia cell line 
KG1a, CD109 is a transforming growth factor (TGF)-β 
co-receptor that binds TGF-β1, regulates TGF-β receptor 
endocytosis and degradation, and suppresses TGF-β/
Smad signalling [19–23]. TGF-β has been found to 
play a role in growth, differentiation and migration; 
dysregulation of TGF-β signalling is associated with 
tissue fibrosis and cancer [21]. CD109 is a monomeric 
170 KDa glycosylphosphatidylinositol (GPI)-anchored 
cell surface protein, a member of the α2-macroglobulin/
Figure 2: MAbs KU42.33C and KU43.13A are directed against distinct epitopes on BxPC-3 human pancreatic 
cancer cells. BxPC-3 cells were grown in 96-well plates to near confluency. MAb KU42.33C was added in doubling dilutions at highest 
concentration of 25 μg/ml for 1 hour on ice. After washing unbound antibodies, increasing concentrations of mAb KU42.33C or mAb 
KU43.13A were added and the total level of bound antibodies were determined as described in Materials and Method section. Data is 
presented as mean absorbance at 450 nm ± SD.
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C3, C4, C5 family of thioester-containing proteins [19, 
21, 24]. CD109 is found on the cell surface of activated 
platelets and T-cells, endothelial cells and a subpopulation 
of CD34+ haematopoietic and progenitor cells, but is 
not expressed in most normal human tissues except for 
myoepithelial cells of mammary, lacrimal and salivary 
glands, and basal cells of bronchial and prostate epithelia 
[19, 20, 23, 25-27]. In addition to the 170 KDa major 
CD109 protein band, the identification of a 150 KDa 
band has been reported and found due to the proteolytic/
autolytic cleavage of the 170 KDa counterpart [19, 25]. 
In agreement, we found that of our two novel antibodies, 
mAb KU42.33C, which targets a sequential epitope on the 
external domain of CD109, detected both the 170 KDa 
and 150 KDa protein bands by immunoprecipitation and 
Western blot (Figure 3A and 3B).
There is currently no comprehensive study 
on the expression pattern of CD109 determined by 
immunohistochemistry and its prognostic significance and 
predictive value for response to therapy in patients with 
pancreatic cancer. In only one study, Haun and colleagues 
examined the expression of CD109 in a panel of eight 
human pancreatic cancer cell lines by Western blot. They 
found high levels of expression in BxPC-3, MIA PaCa-
2, and PANC-1 cells, with no/low expression in A818-
4, AsPC-1, Capan-1, CFPAC-1 and Suit-2 cells [26]. 
These findings are consistent with the results obtained 
with our two anti-CD109 antibodies using ELISA and 
flow cytometry (Figure 1, Supplementary Figures 1 & 
2). They also examined CD109 expression in 18 tissue 
sections from pancreatic ductal adenocarcinoma (PDAC) 
and 11 normal pancreatic tissue samples and found 
positive IHC CD109 staining of variable intensity in 
pancreatic carcinoma cells and completely negative or 
rare cases of focal and weak immunoreactivity in normal 
pancreatic tissue. A substantial difference in CD109 
expression in pancreatic adenocarcinoma compared 
to normal pancreatic tissue was also observed and no 
staining was seen in other pancreatic tissue components 
such as blood vessels, pancreatic acini, stromal fibrous 
tissue, adipose tissue and inflammatory cells [26]. In our 
study, we examined pancreatic cancer tissue arrays of 
samples from 65 patients with different tumour grades 
and 94% of the cases were CD109-positive; we found 
no correlation between the staining intensity and tumour 
grade. The staining predominated in the cytoplasm of 
cancer cells although there some cases of coexisting 
membrane staining (Figures 5C-5G; Supplementary Table 
1). Interestingly, the antibody did not stain normal human 
pancreatic tissue (Figure 5H). No staining was seen in a 31 
out of 33 normal organs in tissue arrays (Supplementary 
Table 2).
Table 1: Identification of proteins recognised by novel mAbs KU42.33C and KU43.13A by mass spectrometry
Band No. mAb Protein HitsMatches/Sequences
1 KU42.33C Q6YHK3 CD109 antigen OS=Homo sapiens GN=CD109 PE=1 SV=2Mass: 162500 Score: 381 Matches: 6(6) Sequences: 6(6)
Start-End Score Peptide
375–385 45 K.LSDSWQPR.S
649–663 48 K.FLIDTHNR.L
859–872 64 R.ADGNQLTLEER.R
879–894 99 K.SYSQSILLDLTDNR.L
1131–
1138 53 K.TLSFSFPPNTVTGSER.V
1220–
1227 73 K.DYIDGVYDNAEYAER.F
2 KU43.13A Q6YHK3 CD109 antigen OS=Homo sapiens GN=CD109 PE=1 SV=2Mass: 162500 Score: 158 Matches: 3(3) Sequences: 3(3)
Start-End Score Peptide
375–385 62 R.ADGNQLTLEER.R
1131–
1138 42 K.LSDSWQPR.S
1220–
1227 54 K.FLIDTHNR.L
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Interestingly, CD109 has been found overexpressed 
in a number of other cancer types including carcinoma 
of the uterine cervix [28], lung squamous cell carcinoma 
[20], cancer of the oral cavity [29], breast cancer [30–
31], malignant melanoma [32], myxofibrosarcoma [23], 
esophageal squamous cell carcinoma [22], squamous 
cell/adenosquamous carcinomas of the gallbladder 
[33], hepatocellular carcinoma [34], nasopharyngeal 
carcinoma [35] and penile squamous cell carcinoma 
[36]. For example, high levels of CD109 expression were 
observed by immunohistochemistry in squamous cell 
carcinomas and premalignant lesions of the oral cavity 
but not in normal tissue, suggesting that CD109 is useful 
in predicting transformation of premalignant lesions into 
cancer [29]. CD109 expression was also found to be more 
frequent in lung squamous cell carcinomas compared with 
other types of lung carcinoma including adenocarcinomas, 
large cell carcinomas and small cell carcinomas; however, 
no association between CD109 expression and the clinical 
stage of the disease was found [20]. Similarly, Dong and 
co-workers showed that CD109 is expressed in bladder 
squamous cell carcinomas and adenosquamous carcinomas 
but not in adenocarcinomas or normal gallbladder tissue 
[33]. A positive correlation has been reported between 
CD109 expression and tumour grade in patients with 
vulvar squamous cell carcinoma [37]. More recently, 
CD109 was found highly expressed in penile squamous 
cell carcinoma and to be a key regulator of the progression 
of lower-grade glioma and therefore a potential molecular 
target for therapy [36, 38].
There is currently conflicting data on the 
prognostic significance CD109 expression in such 
cancers. For example, CD109 expression determined by 
immunohistochemistry in tumour specimens from patients 
with myxofibrosarcoma and hepatocellular carcinoma was 
associated with a poorer prognosis in such patients [23, 
34]. The expression of CD109 has also been reported in 
cancer stem-like cells/cancer-initiating cells (CSCs/CICs) 
in the epithelioid sarcoma cell line ESX, and was found 
to be associated with poor prognosis in patients with soft 
tissue sarcoma [39]. Additionally, a significant association 
was observed between high CD109 expression and low 
1-year survival in patients with diffuse large B-cell 
lymphoma [40]. In contrast, CD109 expression was 
associated with better prognosis in patients with urothelial 
carcinomas [27]. CD109 expression was also found to be 
greater in triple-negative breast cancer (TNBC) compared 
to non-TNBC and to be associated with higher rate of 
distant metastasis and worse postoperative disease-specific 
survival compared to those with low or no expression 
[31]. In agreement, we also found CD109 overexpression 
in the triple negative EGFR overexpressing breast cancer 
cell line MDA-MB-468, but not in the ER-, PR-, HER2 
overexpressing cell line SKBR-3 (Figure 1; Supplementary 
Figure 2). We also found overexpression of CD109 in 
other EGFR overexpressing head and neck squamous 
Figure 3: Immunoprecipitation and immunodetection by Western blot of CD109 antigen with novel mAbs KU42.33C 
and KU43.13A. (A) Immunoprecipitation was performed with novel mAbs KU42.33C and KU43.13A using sheep anti-mouse dynabeads. 
A protein band of ~170 KDa was immunoprecipitated with both novel mAbs. The ~50/25 KDa bands represent heavy and light chains of the 
anti-mouse antibody, respectively. (B) CD109 antigen was immunoprecipitated and probed with novel mAbs KU42.33C and KU43.13A. 
CD109 was immunodetected by mAb KU42.33C but not by mAb KU43.13A. (C) CD109 antigen was immunoprecipitated with mAbs 
KU42.33C and KU43.13A and subsequently immunodetected with commercial anti-CD109 mAb. MWM: molecular weight marker.
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Figure 4: Internalisation studies of novel mAbs KU42.33C and KU43.13A in BxPC-3 human pancreatic cancer cells determined by (A) 
immunofluorescence, and (B) ELISA. BxPC-3 cancer cells were grown to near confluency and incubated with purified antibodies (50 μg/
ml) or control (PBS/1% BSA) at 4ºC for 1 h and subsequently at 37ºC for extra 30 min to allow internalisation. Cells were then fixed, 
permeabilised and incubated with FITC-conjugated or HRP-linked anti-mouse secondary antibodies for immunofluorescence staining 
(200x magnifications) and ELISA respectively. The anti-EGFR mAb HM43.16B. was used as a control (arrows: internalised antibody). 
ELISA results (B) are presented as mean absorbance ± SD.
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cell carcinoma cell line HN5 (Figure 1; Supplementary 
Figure 2). More recently, CD109 was reported to act as 
a novel pro-metastatic factor in a lung adenocarcinoma 
mouse model, and high levels of CD109 resulted in the 
activation of Jak-Stat3 signalling pathways in cancer cells 
suggesting that the direct targeting of CD109 could be of 
therapeutic benefit in the neoadjuvant or adjuvant setting 
[41]. While the soluble recombinant form of CD109 
was reported to be capable of binding to TGF-β and 
antagonising TGF-β signalling and cellular responses in 
experimental system [42, 43], it remains unclear whether 
patients with pancreatic cancer or any other cancer type 
Figure 5: Examples of immunohistochemical staining of formalin-fixed, paraffin-embedded BxPC-3 cancer cell pellets (A-B) and 
pancreatic cancer tissue arrays (C-H) using novel mAbs KU43.13A (5 μg/ml; A) and KU42.33C (5 μg/ml; B-H). Negative and strong 
staining of BxPC-3 cell pellets with mAb KU43.13A (A) and mAb KU42.33C (B) respectively (magnification 200x). Representative 
images of staining of pancreatic cancer specimens in tissue arrays: (C) 1+ cytoplasmic staining, magnification 200x; (D) 1+ cytoplasmic/
membranous staining, magnification 200x; (E) 2+ cytoplasmic/membranous staining, magnification 200x; (F) 2+ cytoplasmic/membranous 
staining, magnification 400x; (G) 2+ membranous staining with perineural invasion, magnification 400x; (H) Negative staining in normal 
pancreas, magnification 200x.
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shed CD109 antigen into their sera and any other body 
fluids and if so, whether CD109 may confer diagnostic, 
prognostic and predictive values, and therefore warrants 
further investigation. Finally, while TMAs are commonly 
employed in medical research, the heterogeneous nature of 
both tumour and stroma in patients with pancreatic cancer 
support the need for further investigations on the relative 
expression and prognostic significance of CD109 in a 
larger group of patients using the whole tumour sections 
or several TMA cores from the same tumours [44, 45]
In summary, our results suggest that high expression 
of CD109 is common in pancreatic cancer. We believe 
that our two novel anti-CD109 mAbs, which are directed 
against two distinct epitopes on the extracellular domain 
of CD109, are ideal tools for conducting detailed studies 
of the biological significance and diagnostic, prognostic 
and predictive values of CD109 in human cancers. 
To our knowledge, there is currently no study on the 
importance of CD109 as target for therapy with mAbs in 
pancreatic cancer or any other type of cancer. Moreover, 
at present, the great majority of FDA approved therapeutic 
antibodies against tumour associated antigens (e.g. anti-
CD20, anti-CD30, anti-EGFR, anti-HER-2 mAbs) are 
the humanised/chimeric IgG1 version of the mouse 
mAbs due to their superior ADCC (antibody-dependent 
cell-mediated cytotoxicity) and/or CDC (complement-
dependent cytotoxicity) functions, or conjugated to toxins 
and radioactive substances to deliver lethal doses of such 
agents to the tumour. A major reason being that, with the 
exception of growth factor receptor blocking antibodies 
(e.g. anti-EGFR mAbs), treatment with the majority 
of naked mAbs do not inhibit the growth in vitro and 
migration of tumours overexpressing the target antigens [9, 
17–18, 46]. As treatment with our two anti-CD109 mAbs 
did not affect the proliferation or migration of CD109 
overexpressing cancer cell lines, further investigations 
are warranted to determine the therapeutic potential of 
the humanised IgG1 or the conjugated versions of such 
antibodies, for use in targeted therapy of tumours with 
CD109 overexpression.
MATERIALS AND METHODS
Cancer cell lines and cell culture
A panel of ten human pancreatic cancer cell lines 
was used in this study: BxPC-3, Capan-2, MIA PaCa-2, 
PANC-1, AsPC-1, HPAF-II, CFPAC-1, Capan-1, Hs766T 
and FA-6 [47]. BxPC-3, PANC-1, MIA PaCa-2 and SP2 
myeloma cells were purchased from European Collection 
of Cell Cultures (ECACC, UK). AsPC-1, Capan-2, 
HPAF-II, Hs766T and CFPAC-1 were purchased from 
American Type Culture Collection (ATCC, UK). Capan-1 
was kindly provided by Dr Charlotte Edling (Barts and 
The London School of Medicine and Dentistry) [47]. 
The EGFR overexpressing head and neck squamous cell 
carcinoma (HN5) and the breast carcinoma cell lines 
MDA-MB-468 and the HER-2 overexpressing SKBR-3 
were also used as described previously [48]. MIA PaCa-2, 
PANC-1, Capan-1, MDA-MB468 and SKBR3 cells were 
authenticated by LGC Standards (Teddington, UK).
All cancer cell lines were cultured routinely at 
37ºC in a humidified atmosphere with 5% CO2. BxPC-
3, AsPC-1, Capan-1 and FA-6 were cultured in RPMI-
1640 medium, MIA PaCa-2, PANC-1 and Hs 766T 
in Dulbecco’s Modified Eagle’s Medium, HPAF-II in 
Eagle's Minimum Essential Medium, CFPAC-1 in Iscove's 
Modified Dulbecco's Medium and Capan-2 in McCoy's 
5a Medium Modified. Cells were supplemented with 10% 
Foetal Bovine Serum (FBS) and antibiotics penicillin (50 
units/ml), streptomycin (0.05 mg/ml) and neomycin (0.1 
mg/ml). RPMI-1640 medium, Eagle's Minimum Essential 
Medium and Iscove's Modified Dulbecco's Medium were 
supplemented with 2 mM, 4 mM and 8 mM L-Glutamine 
respectively. MDA-MB-468, SKBR-3, HN5 and SP2 cells 
were grown in Dulbecco’s Modified Eagle’s Medium 
supplemented with 10% FBS and antibiotics. All culture 
media and additives were purchased from Sigma Aldrich, 
UK.
Generation of novel monoclonal antibodies
The mice immunisation was performed at St 
George’s University of London, following the ethical 
approval and under Home Office animal license. Female 
BALB/c mice (aged 5-6 weeks) were immunised 
repeatedly with subcutaneous flank injections plus 
an intraperitoneal (i.p.) injection of BxPC-3 human 
pancreatic cancer cells (3 sites; 100 μl per site) with a total 
number of 10 million tumour cells per immunisation per 
mouse. Immunisation was repeated 2 times every 2 weeks 
and the final injection was administered 3-4 days before 
collection of lymphocytes from the spleen of immunised 
mice. Spleens were removed from the immunised animals 
by blunt dissection, disaggregated, and the cells washed, 
centrifuged and resuspended in a freezing down solution 
for storage in liquid nitrogen until the date of fusion.
B-lymphocytes derived from the spleen of 
immunised mice were fused with SP2 myeloma cells, 
facilitated by 50% polyethylene glycol (PEG; Sigma 
Aldrich). Cells were cultured in HAT medium (Sigma 
Aldrich) supplemented with 20% FBS, 10% Hybridoma 
Cloning Supplement (Santa Cruz Biotechnology, UK) and 
antibiotics. Newly formed hybridomas were screened by 
ELISA, cloned twice by limiting dilution technique, grown 
in roller bottles and the hybridoma supernatants were 
harvested. Isotyping of novel mAbs was determined using 
a mouse mAb isotyping kit (AbD Serotec, UK) according 
to the manufacturer’s protocol and the antibodies were 
purified by affinity chromatography (below).
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Antibody screening by ELISA and flow 
cytometry analysis
Antibodies secreted by novel hybridomas were 
screened by ELISA. Briefly, cancer cells were seeded 
in 96-well plates and incubated until near confluent. 
Cells were washed once and then incubated with novel 
hybridoma supernatants or purified mAbs (25 μg/ml) 
on ice for 1 h, followed by incubation with 50 μl HRP-
conjugated rabbit anti-mouse secondary antibody (1:1000, 
STAR13B, AbD Serotec) on ice for 45 min. Cells were 
washed and then 50 μl TMB (3,3',5,5'-Tetramethylbenzi
dine; Sigma Aldrich) added to each well and left for ~15 
min at room temperature; the TMB reaction was stopped 
by adding 50 μl of 0.5 M sulphuric acid (H2SO4) to each 
well. Positive and negative controls were included. The 
absorbance of each sample was measured at 450 nm using 
a Biotek plate reader (Biotek, UK).
The cell surface expression of target antigens 
recognised by novel mAbs was determined using flow 
cytometry as described previously [49]. Briefly, cells were 
dissociated from the tissue culture flasks using enzyme-
free cell dissociation buffer (Fisher Scientific, UK). 
Approximately 1x106 tumour cells were incubated with 
novel mouse mAbs KU42.33C or KU43.13A (10 μg/ml) 
or control (i.e. PBS) by rotation for 1 h at 4ºC, followed 
by incubation with FITC-conjugated goat anti-mouse IgG 
secondary antibody (1:200; STAR9B, AbD Serotec) for 45 
min at 4ºC. A minimum of 10,000 events were recorded 
by excitation with an argon laser at 488 nm and analysed 
using the FL-1 detector (FITC detector; 525 nm) of a BD 
FACScalibur flow cytometer using CellQuest Pro software 
(Becton-Dickinson Ltd, UK).
Purification of novel monoclonal antibodies
The purification of mAbs was performed by 
affinity chromatography. Briefly, novel mouse mAbs 
were purified by salt fractionation (solid ammonium 
sulphate ([NH4]2SO4; 45% of saturation - 270 g/L; Fisher 
Scientific) followed by affinity chromatography using a 5 
ml HiTrap Protein G HP column in an ÄKTAprime plus 
chromatography system (both from GE Healthcare, UK). 
The antibody sample was loaded into the HiTrap Protein G 
HP column pre-equilibrated with 25 ml binding buffer (0.1 
M phosphate buffer, 0.15 M NaCl, pH 7.4) at a flow rate of 
1 ml/min. Unbound proteins were removed by washing the 
column with 50 ml binding buffer and bound antibodies 
were eluted with 25 ml elution buffer (0.1 M glycine, 
pH 2.5). Selected fractions were pooled together and 
subjected to buffer exchange with PBS using the HiPrep 
26/10 Desalting column (GE Healthcare Life Sciences). 
Following buffer exchange, the purified antibodies were 
filtered through a 0.2 μM syringe filter (Merck Millipore, 
UK), aliquoted and stored at -20ºC for further studies.
Competitive binding assay
BxPC-3 cancer cells were seeded in 96-well plates 
and incubated until they became near confluent. Cells 
were washed once with serum-free DMEM and increasing 
amounts of mAb KU42.33C were added to different 
wells in duplicates until near saturation point. Thereafter, 
increasing concentrations of either mAb KU42.33C or 
KU43.13A were added in duplicates and incubated on 
ice for 1 hour. Following washing, 50 μl HRP-conjugated 
rabbit anti-mouse secondary antibody (1:1000, STAR13B, 
AbD Serotec) was added and incubated on ice for 45 min. 
Cells were washed again three times and 50 μl TMB added 
to each well and left for ~15 min at room temperature; 
the TMB reaction was stopped by adding 50 μl of 0.5 M 
sulphuric acid (H2SO4) to each sample and its absorbance 
measured at 450 nm.
Internalisation studies
Immunofluorescence staining of tumour cells and 
ELISA were used to determine whether treatment with 
novel antibodies resulted in down-regulation of the target 
antigen. Briefly, BxPC-3 cancer cells were grown to near 
confluency in RPMI/10% FBS in Lab-Tek 8-well chamber 
slides (VWR, UK) or 96-well plates, respectively. Cells 
were incubated with mAbs KU42.33C or KU43.13A (50 
μg/ml), or negative control (i.e. PBS/1%BSA alone) for 1 
h at 4ºC to allow antibody binding, followed by incubation 
at 37ºC for 30 min to allow antibody internalisation. The 
anti-EGFR mAb HM43.16B was used as another control 
in this study [50]. A control slide was maintained at 4ºC. 
Cells were fixed with 4% formaldehyde for 10 min, 
the cell membrane permeabilised with 0.5% Triton-X 
100 for 15 min and non-specific binding blocked with 
PBS/1%BSA for 1 h at 4ºC. Cells in immunofluorescence 
slides were then incubated with Alexa Fluor 488 secondary 
antibody (1:200; Fisher Scientific) for 1 h at 4ºC, mounted 
in Vectashield with DAPI (Vector laboratories, UK) and 
examined using Nikon eclipse i80 microscope and Nikon 
NIS-Elements software as described previously [51]. Cells 
in ELISA plates were incubated with HRP-conjugated 
rabbit anti-mouse secondary antibody and the absorbance 
of each sample measured at 450 nm.
Cell growth studies
The effect of novel mAbs on the growth of 
human cancer cell lines was investigated using the 
Sulforhodamine B (SRB) colorimetric assay [47, 49]. 
Approximately 5x103 tumour cells per well were seeded 
in 96-well plates containing medium supplemented with 
2% FBS in the presence of mAbs (300 nM) or control 
medium. AsPC-1 and HPAF-II cancer cells were grown 
in 5% FBS medium as they did not grow well in 2% FBS 
medium. A (no treatment) control plate was included under 
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the same conditions (4 h incubation at 37ºC) to determine 
the initial number of cells before treatment. Cells were 
cultured until the controls became almost confluent (4-10 
days). Tumour cells were fixed with 10% trichloroacetic 
acid (TCA; Fisher Scientific), stained with 0.4% SRB 
(Sigma Aldrich) in 1% acetic acid and solubilised with 
Tris-base (10 mM, pH 10; Fisher Scientific) before plate 
reading. Gen5 software was used to determine the IC50 
through non-linear least squares curve fitting [47, 49].
Migration assay
The effect of novel mAbs on the migration of 
human pancreatic cancer cells BxPC-3, AsPC-1 and 
CFPAC-1 was investigated using the IncuCyte ZOOM® 
Live-Cell Imaging instrument (Essen Bioscience, UK) 
as described previously [52]. Approximately 1x103 
cancer cells per well were seeded in duplicates in 0.5% 
FBS medium in an IncuCyte™ ClearView 96-well Cell 
Migration Plate (Essen Bioscience, UK) along with 300 
nM mAbs or control (i.e. medium alone). The cells were 
allowed to settle for 15 min at room temperature before 
transfer to an incubator at 37ºC for 30 min to pre-incubate 
the cells in the presence of treatment. Then, 200 μl of 
chemoattractant (i.e. 10% FBS medium) or control (i.e. 
0.5% FBS medium) were added to the appropriate wells 
of the reservoir plate and the insert plate placed into the 
pre-filled reservoir plate. The plate was then transferred 
to the IncuCyte ZOOM® Live-Cell Imaging Instrument 
(Essen Bioscience) and allowed to warm to 37ºC for 15 
min before any condensation accumulated on the plate 
lid or bottom was wiped away. The plate was imaged at 
10x objective using the Chemotaxis Scan Type - Phase 
channel. The IncuCyte™ Chemotaxis Cell Migration 
Software Module (Essen Bioscience) was used for data 
analysis. Whole-well images of cells on both the bottom 
and the top of the plate membrane were captured every 
2 h over 48 h and all images were processed using 
automatic algorithms to quantify cell area on each side of 
the membrane.
Immunoprecipitation and mass spectrometry
To identify the target antigens recognised by the 
antibodies, immunoprecipitation and mass spectrometry 
were performed. Briefly, novel mAbs (5 μg) were 
incubated with 1 ml BxPC-3 tumour cell lysates (lysis 
buffer containing 50 mM Tris-HCl pH 7.2, 150 mM NaCl, 
2 mM MgCl2, 2 mM CaCl2, 0.1% NaN3, 100 mM DTT, 
1% Triton X-100, 50 mM N-ethylmaleimide) overnight at 
4ºC by gentle rotation (14 rpm), and then incubated with 
50 μl pre-washed Dynabeads sheep anti-mouse IgG for 
1 h at 4ºC. The immunocomplexes were captured on a 
DynaMag™-2 for 2 min, the supernatants aspirated and 
the samples washed 3 times with PBS. The complexes 
were then eluted by mixing beads with LDS sample buffer 
(25% NuPAGE LDS buffer [4x], 10% reducing agent 
[10x] and 65% distilled water; Invitrogen, UK), heated to 
95ºC for 5 min and analysed by SDS-PAGE.
Identification of isolated protein was performed 
by mass spectrometry at the University of York. Desired 
bands were excised and in-gel digested with trypsin. 
Positive-ion MALDI mass spectra were obtained using a 
Bruker ultraflex III in reflectron mode, equipped with a 
Nd:YAG smart beam laser. MS spectra were acquired over 
a mass range of m/z 800-5000. Final mass spectra were 
externally calibrated against an adjacent spot containing 
6 peptides (des-Arg1-Bradykinin, 904.681; Angiotensin 
I, 1296.685; Glu1-Fibrinopeptide B, 1750.677; ACTH 
(1-17 clip), 2093.086; ACTH (18-39 clip), 2465.198; 
ACTH (7-38 clip), 3657.929). Monoisotopic masses 
were obtained using a SNAP averaging algorithm (C 
4.9384, N 1.3577, O 1.4773, S 0.0417, H 7.7583) and a 
S/N threshold of 2. For each spot, the ten strongest peaks 
of interest, with a S/N greater than 30, were selected for 
MS/MS fragmentation. Fragmentation was performed in 
LIFT mode without the introduction of a collision gas. The 
default calibration was used for MS/MS spectra, which 
were baseline-subtracted and smoothed (Savitsky-Golay, 
width 0.15 m/z, cycles 4); monoisotopic peak detection 
used a SNAP averaging algorithm (C 4.9384, N 1.3577, 
O 1.4773, S 0.0417, H 7.7583) with a minimum S/N of 
6. Bruker flexAnalysis software (version 3.3) was used to 
perform the spectral processing and peak list generation 
for both the MS and MS/MS spectra. Tandem mass 
spectral data were submitted to database searching using 
a locally-running copy of the Mascot program (Matrix 
Science Ltd., version 2.1), through the Bruker BioTools 
interface (version 3.2). Search criteria included: Enzyme, 
Trypsin; Fixed modifications, Carbamidomethyl (C); 
Variable modifications, Oxidation (M); Peptide tolerance, 
100 ppm; MS/MS tolerance, 0.5 Da; Instrument, MALDI-
TOF-TOF. UniProt_human_SP database was used for 
protein identification.
Western blotting
The ability of the novel antibodies to recognise the 
target antigen in Western blot was performed. Briefly, 
protein immunoprecipitated with novel mAbs KU42.33C 
and KU43.13A (5 μg) was analysed by SDS-PAGE under 
reducing conditions, prior to Western blotting. The transfer 
of proteins from 4-12% Bis-Tris-gels to Immobilon-
FL PVDF membranes (Merck Millipore, UK) was 
performed using the XCell II™ Mini-Cell Blot Module 
kit (Invitrogen, UK) at a constant voltage of 30 V on ice 
for 2 h. PVDF membranes were probed with novel mAbs 
(30 μg/ml) or commercial anti-CD109 mAb (1:100; sc-
365780; Santa Cruz Biotechnology, UK) overnight at 4ºC 
and subsequently incubated with secondary goat anti-
mouse antibody (1:10,000; LI-COR Biosciences, UK) for 
1 h at room temperature. For visualisation, the blots were 
analysed using the Oddysey® CLx instrument (LI-COR 
Biosciences).
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Immunohistochemical examination of tumours
BxPC-3 cell pellets were used to determine whether 
novel antibodies can be used for detection of the target 
antigen in formalin-fixed paraffin-embedded tissues 
and for further optimisation of the primary antibodies. 
Then, the expression level of the target antigens was 
determined in human pancreatic cancer tissue arrays (35 
cases in early stage, 35 cases in advance stage and 10 
cases normal tissue; Cat. No. PA804a, Biomax US) and 
normal organ tissue arrays (33 types of normal tissue; Cat. 
No. MNO661, Biomax US) by the mAb. Briefly, tissue 
sections were deparaffinised and rehydrated through a 
series of alcohols followed by antigen retrieval with Tris-
EDTA buffer (10 mM TrisBase, 1 mM EDTA, 0.05% 
Tween 20, pH 9.0). Then, the mouse-specific HRP/DAB 
(ABC) Detection IHC Kit (Cat. No. ab64259, Abcam, 
UK) was used according to the manufacturer instructions. 
Briefly, tissue sections were incubated with hydrogen 
peroxide block for 10 min, followed by protein block for 
5 min and subsequent incubation with novel mAbs (5 
μg/ml) overnight at 4 °C. Following washing, the tissue 
sections were incubated with biotinylated goat anti-mouse 
secondary antibody for 10 min, followed by streptavidin 
peroxidase for another 10 min. After washing, the 
colorimetric reaction was developed by incubation with 
DAB substrate plus chromogen for 5 min. The slides were 
counterstained with Harris Haematoxylin (VWR, UK) 
for 2 min and rinsed with water. The tissue sections were 
then dehydrated through a series of alcohols and the slides 
mounted in DPX mounting medium (VWR) and examined 
for the expression level and intensity of staining (i.e. 1+ 
weak, 2+ moderate, 3+ strong).
Statistical analysis
Statistical analysis was performed using the 
Statistical Package for the Social Sciences (SPSS) version 
23 (SPSS UK Ltd, Woking, UK). The unpaired two-tailed 
Student's t-test was used to compare mean values between 
two groups. Data are presented as mean ± SD. P ≤ 0.05 
was considered statistically significant.
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